TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02681965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAN book/videos
Description: The intervention focuses on achieving long lasting lifestyle changes to achieve weight loss and maintenance. Women randomized to the weight loss program will receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity.
Study: NCT05343156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone nanoparticles eye drops
Description: DexNP 15 mg/mL eye drops 3 times a day (every 8 hours) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone nanoparticles eye drops
Description: DexNP 15 mg/mL eye drops 3 times a day (every 8 hours) for 12 weeks
Study: NCT02608853

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.
Study: NCT00663871

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soybean Oil (Placebo)
Description: Participants will take 2 grams of soybean oil supplements on a daily basis.
Study: NCT04353908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The Kabat procedure consists of facilitating the voluntary response of an impaired muscle through a global pattern of an entire muscular section which undergoes resistance. This method considers that harmony, coordination and optimal strength of body movements mainly depend upon the fact that they are performed following diagonal lines with respect to the sagittal axis of the body, thus implying a 'rotational' effect. It will performed twice a week for 8 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The Kabat procedure consists of facilitating the voluntary response of an impaired muscle through a global pattern of an entire muscular section which undergoes resistance. This method considers that harmony, coordination and optimal strength of body movements mainly depend upon the fact that they are performed following diagonal lines with respect to the sagittal axis of the body, thus implying a 'rotational' effect. It will performed twice a week for 8 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen Injection
Description: With an insulin-type syringe and 30-gauge needle, a bolus of about 0.4 cc per point of the collagen solution will be injected in the orbicularis oculi muscle 1 cm outside the orbital rim and 0.5 cm superior and inferior to the first injection point, respectively, and in the orbicularis oris muscle, where the 2 injection points are on the border between the pars peripheralis and pars marginalis, located about 5 mm above the superior and inferior vermilion, respectively
Study: NCT04323670

Intervention type: DEVICE
Group type: OTHER
Intervention: Selectra 3D guiding catheter
Description: His lead measurements
Study: NCT01925313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30044
Description: 20.51mg a day,PO,QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TALION TAB. 10mg
Description: 10mg a day,PO,BID
Study: NCT02744352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20ml bolus of 0.5% ropivicaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20ml bolus of 0.5% ropivicaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% of ropivacaine at 8 milliliter/hour
Description: Local anesthetic
Study: NCT01569152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8457 100 mg
Description: MK-8457 100 mg dosed orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8457 100 mg
Description: MK-8457 100 mg dosed orally BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose-Matched Placebo
Description: Dose-matched placebo dosed orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX dosed at the stable dose receive upon study entry

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: MTX dosed at the stable dose receive upon study entry

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX dosed at the stable dose receive upon study entry
Study: NCT03057899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFG capsules (200 mg /capsule)
Description: TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
Study: NCT03493100

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplementation
Description: The intervention group will receive optimized nutritional support, by ONS. While hospitalized each patient receives 2 portions of oral supplementation per day. For remaining days supplementation is calculated individually according to a sarcopenia/energy balance schema resulting in none or maximum 2 portions per day.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The control group will receive treatment according to usual care.
Study: NCT03777033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic protocol with Ca and Vit D
Description: 3g calcium /day for 5 days and then 2g/day for 10 days 2 Micrograms Alfacalcidol/day and then 1 microgram /day for 10 days~the Prophylactic protocol with Ca and Vit D will be given in the form of Alfacalcidol 0.5 Micrograms Capsule and CALCIUM CARBONATE + CALCIUM GALACTOGLUCONATE 1000mg tablet
Study: NCT01024933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect/Self-Affirmation/Motivational Interviewing
Description: The PASA group-intervention will receive small gifts one week prior to their scheduled follow up. The PASA intervention involves reminding participants to think about their proud and positive moments. The motivational interviewing intervention includes assessing the patient's motivation and confidence; elicit barriers and concerns; summarize in a non-threatening manner the 'pros' and 'cons' of patient's concerns, thereby eliciting positive self-motivational statements about the behavior. Follow up will be every two months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational and Behavioral
Description: The Education and Behavioral Contract (Control group)will receive an educational workbook and behavioral contract. In addition, each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
Study: NCT00423956

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Repairing Induced tooth root resorption by ultrasound
Description: Repairing Induced tooth root resorption by ultrasound
Study: NCT04538040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
Description: Safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine in male, 45+ year old subjects. The study will also include secondary outcomes of quality of life (QOL) and weight changes.
Study: NCT00819247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given as a subcutaneous injection.
Study: NCT04834245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrogel/nano silver-based dressing
Description: compare the effectiveness of using hydrogel/nano silver-based dressing vs. traditional dressing on diabetic foot wound healing.
Study: NCT02899130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyherbal
Description: Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive compound that is similar looking as the intervention
Study: NCT03295643

Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile smoking cessation program and CO breath sensor device
Description: Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
Study: NCT00902083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p53 gene with surgery
Description: pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: remove tumor surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p53 with chemotherapy
Description: p53 gene treatment: 10exp12 virus particles per 3 days for 10 times Chemotherapy: standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p53 gene therapy
Description: p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
Study: NCT02718495

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTI-428

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTI-428

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTI-428

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00635921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone
Description: Dose flexible from 40 to 200 mg/d during 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: flexible doses from 40 to 200 mg/d during 12 weeks
Study: NCT00396474

Intervention type: OTHER
Intervention: post GH treatment observational study
Description: Intravenous glucose tolerance test (IVGTT)
Study: NCT03792542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib Hydrochloride ( 12mg, quaque die（QD）, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from adverse events(AEs), they can get declined dosage.
Study: NCT03453814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Subjects will receive one hour of music twice a day for three days.
Study: NCT03566381

Intervention type: DEVICE
Intervention: Application of a soft patch composed of medical-grade silicone that collects sweat during a subject's natural behaviors.
Description: This device contains sweat sensors embedded in an elastomer and is applied to the skin with a medical grade adhesive.
Study: NCT02232061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod 0.5 mg tablet
Study: NCT01639703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenetix-CT perfusion imaging
Description: Injection of 50 ml of Xenetix
Study: NCT01427543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MILE intervention
Description: Participants will be asked to attend 6 - 2 hour group sessions over the course of 3 weeks. The intervention aims to reduce HIV risk taking related to sex risk and alcohol and drug use.
Study: NCT02878200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Description: A treatment course of DHAP consists of three doses taken daily. Treatment doses for household members will be prepared based on measured weight
Study: NCT00571103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acamprosate
Description: Two 333mg tablets taken three times daily.
Study: NCT02090387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ONS without AN777
Description: 2 servings a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ONS containing AN777
Description: 2 servings a day
Study: NCT01874626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SST-0225 Topical Ibuprofen Cream
Description: SST-0225 Topical Ibuprofen Cream
Study: NCT01972464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: oral micronized progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01042392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 150 mg Aliskiren as film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 5 mg was given in capsule form.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to Aliskiren
Description: The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo to Aliskiren
Description: The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to Ramipril
Description: The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to Ramipril
Description: The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
Study: NCT03646942

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy
Description: low level laser therapy will be used in order to induce tooth movement. low level laser with a wave length of 830 nm, output of 150 mw, energy of 2 j per point and application time of 15 seconds per point will be applied on each tooth of the six upper incisors according to this protocol: the root will be divided into 2 halves; gingival and cervical. Laser will be applied in the center of each half from both the buccal and palatal sides which means 4 application points and a total energy of 8 Joules/each tooth.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: low level laser therapy will be used in order to induce tooth movement. low level laser with a wave length of 830 nm, output of 150 mw, energy of 2 j per point and application time of 15 seconds per point will be applied on each tooth of the six upper incisors according to this protocol: the root will be divided into 2 halves; gingival and cervical. Laser will be applied in the center of each half from both the buccal and palatal sides which means 4 application points and a total energy of 8 Joules/each tooth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lingual Orthodontics
Description: Lingual braces will be used to conduct the orthodontic treatment of patients with moderate level of crowding on the upper dental arch.
Study: NCT04717089

Intervention type: OTHER
Intervention: overnight intensive recovery / extended post anaesthetic care in PACU
Description: From January 2020, during COVID-19 first pandemics in Hong Kong, a bundle of interim measures was implemented with the joint efforts of the Department of Anaesthesia and Operating Theatre Services (A\&OT) and Intensive Care Unit (ICU), and two ordinary recovery beds were converted into extended post anesthetic care in PACU (ExRR), based on the concept of overnight intensive recovery (OIR) to provide level 2 intensive care to patients undergoing major or ultra-major operations or having multiple comorbidities warranted intensive care in the immediately postoperative periods. This was conducted over 3 pandemic waves in Hong Kong.
Study: NCT00103662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor plus plerixafor
Description: Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granulocyte colony-stimulating factor plus placebo
Description: Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Study: NCT04161521

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Novel Technique of Placenta Accreta in Menoufia University Hospital
Description: * Classical CS to decrease haemorrhage from placental bed.~* Delievery of the fetus.~* At the delivery 10 UI of oxytocin IV will be injected.~* The placenta is not attempted to be delievered.~* Opening of the broad ligament via round ligament division and ligation.~* Gentle dissection of the urinary bladder from lateral to medial.~* Bilateral uterine artery clamping at low level below the placental bed .~* Gentle attempt to deliver The placenta.~* If the placenta is delievered we will do bilateral uterine artery ligation at multiple levels and multiple square compression sutures(if needed) for proper hemeostasis at the placental bed. Then closure of uterine incision.~* If the placenta is not delievered we will do segmental ressection of lower uterine segment including the placenta .~* Intraperitoneal drain insertion.
Study: NCT00664118

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Doula combined analgesia
Description: Doula combined epidural analgesia in the latent phase of first stage of labor in primiparas

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Analgesia without doula
Description: Epidural analgesia in the latent phase of first stage of labor without doula accompany in primiparas
Study: NCT04218279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Health Education
Description: Intervention materials include 10 brief education modules that the target population will review/view on a secure study-specific website.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Health Education
Description: Intervention materials include 10 brief education modules that the target population will review/view on a secure study-specific website.
Study: NCT05823103

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Shawki Septum Scoring System
Description: Utilising the novel scoring system to facilitate feasibility and safety of hysteroscopic metroplasty for uterine septum

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ESHRE ASRM Classification
Description: Utilising the current classification before performing hysteroscopic metroplasty
Study: NCT00715871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Subjects received an amount of liquid nicotine cigarettes (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of liquid nicotine cigarettes received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smoke-Break nicotine delivery device
Description: The Smoke-Break nicotine delivery device is a liquid nicotine cigarette designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive.
Study: NCT02976246

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 (MK7)
Description: One tablet of vitamin K2 (MK7) 360 micrograms given once daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 (MK7)
Description: One tablet of vitamin K2 (MK7) 360 micrograms given once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of placebo given once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of placebo given once daily.
Study: NCT00884260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS (LCS, BAY86-5028)
Description: In Vitro release rate: 12µg LNG/24h
Study: NCT01999764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLT091001
Description: QLT091001 administered orally at multiple time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLT091001
Description: QLT091001 administered orally at multiple time points.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered orally at multiple time points.
Study: NCT00540644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide (Revlimid®)
Description: 25 mg p.o. daily on days 1-21 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg p.o. BID daily on days 1-21 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 50 mg p.o. Q.O.D.